CAPE TOWN (Reuters) – South Africa’s Biovac Institute is aiming to start production of the mRNA COVID-19 vaccine developed by Pfizer and BioNTech in the second half of next year, its chief executive officer said on Wednesday.
Morena Makhoana told Reuters the Cape Town-based firm would ramp up production of the COVID-19 vaccine before reaching output of 100 million doses a year around early 2023.
(Reporting by Wendell Roelf; Editing by Alexander Winning)
